From: The Rheumatologist, November 2007
Disease remission should be the goal for all rheumatologists treating childhood arthritis
Treatment of juvenile idiopathic arthritis (JIA) has a straightforward goal: to achieve disease remission and allow children to grow and develop normally. Several challenges stand in the way. There is a lack of decisive data on the medication (or combination of medications) that can achieve this xaa reliably and the etiology of disease is unknown. The most important targets for therapy among the myriad of documented immunologic abnormalities are not certain.
Recommended reading from A&R and AC&R
Do Side Effects of Anti–TNF-α Therapy Warrant Reconsideration?
Incoming ACR and ARHP presidents tell you what to expect in 2008
When he walks to the podium in Boston for his first official duties, incoming ACR President David A. Fox, MD, will be treading familiar turf. The three-year prelude to presidency - when candidates serve as secretary-treasurer, vice president, and then president-elect - is designed to educate future officers about the full spectrum of the ACR’s membership needs and issues. Dr. Fox found this lead-in period a valuable opportunity to work with and learn from senior staff members and fellow officers....
Arthritis & Rheumatism Celebrates Its 50th Year
Next February marks a major milestone for rheumatology: The ACR’s journal Arthritis & Rheumatism (A&R) turns 50. The first issue of A&R rolled out in February 1958, before rheumatology was even a recognized subspecialty and when new information and research surrounding the field were developing at a breakneck pace.
Pitfalls to avoid and habits that protect you from malpractice suits
Few issues in medicine cause as much worry and angst among physicians as the fear of being sued. The concern about medical malpractice litigation is one the leading causes of career dissatisfaction among physicians.1 Remarkably, little is known about why various subspecialties become involved in litigation, and a PubMed search reveals no articles written specifically on the topic of rheumatology lawsuits.
From the College
As I write this column, we are preparing to meet in Boston for the 2007 ACR/ARHP Annual Scientific Meeting, and my year as the ARHP president is coming to end. It has been a remarkable year for the ARHP, as we have made significant progress toward achieving the goals identified in our Long-Range Plan...
November’s coding challenge
November’s coding answer
Carpal tunnel syndrome (CTS) is possibly the most common nerve disorder experienced today. It affects 3% to 7% of the population and is usually treatable. Middle-age and older individuals are more likely to develop CTS than younger people, and women develop CTS three times more frequently than men.
Ask any rheumatologist about the state of RA as a disease and you’re likely to get the same answer: There’s reason for great optimism and there’s a lot of work to be done.
The annual ACR “Advocates for Arthritis” program will be held in Washington, D.C., February 25–26, 2008. As in previous years, physicians, health professionals, and patients will visit congressional offices to discuss current legislation that would advance research, prevention, and care for patients with arthritis and other rheumatic diseases.
Each year, fraud and abuse cost the Medicare and Medicaid programs billions of dollars. What is the difference between fraud and abuse? The Centers for Medicare & Medicaid Services define fraud and abuse as two different offenses...
The latest development in the healthcare class-action settlement will affect approximately 900,000 physicians (and some major state medical societies) who may be eligible to receive compensation from the settlement - as long as they file a claim. The case has been called “historic” by those representing both physicians and insurance companies.
On September 19, the ACR and the Arthritis Foundation held a joint legislative briefing to inform Congress members and their staff about the devastating effects of arthritis and related rheumatic diseases, as well as to encourage support of the “Arthritis Prevention, Control, and Cure Act of 2007” (S.626/H.R. 1283), or Arthritis Act.
Halsted R. Holman, MD, couples a stellar career with a knack for helping others achieve their potential
By all accounts, Halsted R. Holman, MD, Guggenhime professor of medicine, emeritus, at Stanford Medical School (Calif.), has been a major presence in several different scientific arenas. From a stellar career as a laboratory immunologist, he went on to become chair of medicine when Stanford Medical School relocated to Palo Alto in 1960 and help found and shape the Robert Wood Johnson Clinical Scholars Program. He has been a visionary thinker about patient outcomes measures and the need for a better form of...
Handpicked Reviews of Contemporary Literature
Hydroxychloroquine: The Unsteroid? HCQ Has Many Benefits for Lupus Patients
As TR celebrates one year, we look forward to an exciting 2008
The ACR’s Annual Scientific Meeting is the premier convocation of our specialty and is always a momentous occasion. This year, Boston will be a magnet, pulling rheumatologists and allied health professionals from around the world, patient groups, government, industry, and the media into its orbit for a week to discuss where we are now and where we going. It will be a great week, and I look forward to a fantastic time.
The past year was filled with accomplishments and I take away wonderful memories
I am flying back to San Francisco from Washington, D.C. It is late September, but publishing deadlines require that this column be submitted in a few days. I have been in Washington for a successful legislative briefing on Capitol Hill, as well as the second annual ACR Quality Summit. I will actually be home until the annual meeting because October is the only month all year that I will not get on an airplane for ACR business.